(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0 Puritas ≥98.0% (HPLC) Rivaroxaban Intermedia Factory

Description:

Nomen chemicum: (S)-(+)-Glycidyl Phthalimide

CAS: 161596-47-0

Aspectus: Alba ad Off-White pulveris

Puritas: ≥98.0% (HPLC)

Medium Rivaroxaban (CAS: 366789-02-8) in tractatione Thromboembolismi Venosti (VTE)

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple Rivaroxaban intermedia:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl) morpholin-3-one CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acidum CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8

Chemical Properties:

Nomen chemicum	(S)-(+)-Glycidyl Phthalimide
Synonyma	(S)-Glycidyl Phthalimide;(S)-N-Glycidylphthalimide;Rivaroxaban Medium
CAS Number	161596-47-0
CATTUS Number	RF-PI128
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C11H9NO3
M. Pondus	203.19
Liquescens punctum	102℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White pulveris
Lepidium sativum	HPLC
Damnum in Siccatio	≤0.50%
Sulphate Cinerum	≤0.50%
Puritas / Analysis Methodus	≥98.0% (HPLC)
Phthalimides	≤0.10%
Uno Max Impurity	≤0.50%
Totalis immunditias	≤2.0%
Epichlorohydrin	≤0.10%
Glycidol	≤0.10%
Chiral Puritas	R-isomer ≤2.0% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	Rivaroxaban (CAS: 366789-02-8) Intermediate

(S)-(+)-Glycidyl Phthalimide CAS: 161596-47-0 Synthesis Route

Sarcina & Repono:

commoda:

FAQ:

Applicatio:

Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica et elit (S)-(+)-Glycidyl Phthalimidis (CAS: 161596-47-0) cum qualitate alta.Medium proprie est in synthesi Rivaroxaban (CAS: 366789-02-8), in tractatione Thromboembolismi Venosti (VTE).

Rivaroxaban (Xarelto; CAS: 366789-02-8) medicamentum antithromboticum est et elaboratum est in collaboratione pharmaceutica inter Germanos Bayer et Johnson comitatus Americanos.Rivaroxaban indicatur curationem venae profundae thrombosis et embolismi pulmonis, et praeventionis recurrentis venae profundae thrombosis et embolismi pulmonis in adultis.